Sexual health

Suppressive Versus Episodic Herpes Treatment

Save

Herpes has no cure, but that doesn't mean there's only one way to manage it. Suppressive and episodic therapy take genuinely different approaches — one taken daily regardless of symptoms, the other taken only when an outbreak begins — with different tradeoffs for outbreak frequency and transmission risk. This piece lays out who tends to benefit from each, how they compare on protecting a partner, and why the choice isn't permanent.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What's the difference between suppressive and episodic herpes therapy?

Suppressive therapy means taking an antiviral medication every day, indefinitely, to keep outbreaks from starting in the first place and to lower the chance of passing the virus to a partner 1. Episodic therapy means taking the same category of medication only when an outbreak begins, for a short course aimed at shortening that specific episode, an approach documented alongside suppressive therapy in the current U.S. treatment guidelines 2.

This is a different question from is herpes curable — herpes has no cure regardless of which treatment strategy someone uses; the choice here is about managing outbreaks and transmission risk, not eliminating the virus 1. Both approaches are recognized, evidence-based ways to manage genital herpes, and neither is inherently the 'right' one — the choice depends on how often outbreaks happen, how much transmission risk matters to a person and their partner, and simple preference about taking a daily medication versus reaching for one only when needed 2.

Who tends to do better with daily suppressive therapy?

People with frequent outbreaks, generally several or more a year, tend to get the most out of suppressive therapy, since taking medication daily prevents most episodes before they start rather than treating them one at a time. It also lowers, though does not eliminate, the amount of virus shed between outbreaks, which is the mechanism behind its transmission-reduction benefit 1.

Someone in an ongoing relationship with a partner who does not have herpes is often a candidate for this reason specifically — suppressive therapy is one of the clearer tools available for lowering transmission risk over time, alongside consistent condom use. It's also a reasonable choice for someone who simply finds outbreaks disruptive enough that preventing most of them outweighs taking a daily medication.

Who might do fine with episodic treatment instead?

Someone with infrequent outbreaks, long stretches without any recurrence, or a strong personal preference against a daily medication may reasonably choose episodic treatment instead, taking medication only at the first sign of an outbreak 2. Understanding what triggers a herpes outbreak can help someone using this approach recognize the early tingling or discomfort that signals one is starting, since acting quickly is what makes episodic treatment work well.

Episodic treatment does less for transmission risk than suppressive therapy does, since it doesn't reduce asymptomatic shedding on the many days without any outbreak at all. That tradeoff is worth naming honestly rather than assuming episodic treatment offers the same protection suppressive therapy does.

Does daily therapy actually lower the chance of passing it to a partner?

Yes — daily suppressive therapy is specifically recommended, in part, because it reduces the risk of transmitting genital herpes to a partner, on top of reducing a person's own outbreak frequency 1. That transmission benefit is one of the more well-established reasons clinicians bring up suppressive therapy even for someone whose own outbreaks are mild or infrequent.

It doesn't reduce that risk to zero. Combining daily therapy with consistent condom use adds another layer, since condoms are highly effective against STIs spread through genital fluids but only partially protective against infections like herpes that spread through skin-to-skin contact 3. Neither tool alone, and not even both together, eliminates transmission risk entirely — a reality worth raising directly in any conversation about dating with herpes, rather than leaving a partner to assume more protection than actually exists.

How does someone even get to this conversation? Testing and diagnosis

Routine blood testing for herpes in someone without symptoms is not recommended, since standard serologic tests carry a high false-positive rate in that group 4. Testing an active sore directly, when one is present, is a more reliable way to reach an actual diagnosis than a blood draw taken with no symptoms at all 5.

That means the suppressive-versus-episodic decision usually starts after a diagnosis has already been made, whether through a tested outbreak or a partner's diagnosis prompting a conversation. The herpes blood test window and how seroconversion timing affects accuracy is a more detailed topic than the diagnosis question covered briefly here, worth reading for anyone testing after a specific concern rather than a visible outbreak.

What practical factors go into the decision, beyond outbreak frequency?

Outbreak frequency is the main clinical factor, but day-to-day logistics matter too, and they're worth naming directly rather than treating the decision as purely medical. Episodic treatment only works if medication is already on hand and started right at the first sign of an outbreak, which means having a supply ready in advance rather than waiting to call a pharmacy once symptoms start.

Suppressive therapy trades that unpredictability for a daily habit, which suits some people well and feels like an unwelcome routine to others — missed doses don't cause immediate harm the way skipping a dose of some other medications might, but consistency is what makes the transmission-reduction benefit hold up over time 1. Cost and insurance coverage can also tip the decision one way or another, since a daily prescription and an as-needed one are billed differently depending on the plan, which is a reasonable thing to ask a pharmacist or clinician about directly rather than assuming either option is automatically cheaper.

Can the two approaches be switched, or combined over time?

Yes. Neither suppressive nor episodic therapy is a permanent commitment, and it's common for the choice to shift as outbreak frequency changes, as a relationship changes, or simply as a person's preference changes 2. Someone might start with episodic treatment, move to suppressive therapy during a period of frequent outbreaks or a new relationship, and move back later.

There's no penalty for switching, and no reason to treat the initial choice as final. What actually happens day to day while living with herpes, including timing around symptoms and disclosure conversations with a partner, goes well beyond a single treatment decision and is covered in more depth for anyone newly navigating a diagnosis.

Common questions

No. Neither suppressive nor episodic therapy cures herpes — there is no cure for either HSV-1 or HSV-2. Suppressive therapy manages the virus by preventing most outbreaks and lowering transmission risk when taken daily; it doesn't remove the virus from the body.

There's no single cutoff, but people with several or more outbreaks a year, or anyone especially concerned about transmission risk to a partner, tend to be the clearest candidates. It's a conversation worth having with a clinician based on actual outbreak pattern rather than a fixed number.

It works best started as early as possible, ideally at the very first sign of an outbreak — tingling or discomfort before a visible sore appears. Waiting longer into an outbreak generally makes episodic treatment less effective at shortening it.

Yes, and it's common. Outbreak frequency, relationships, and personal preference all change over time, and the choice between daily and as-needed treatment can be revisited with a clinician whenever it no longer fits.

No. It meaningfully lowers the risk of transmission but doesn't eliminate it. Combining daily therapy with consistent condom use adds another layer of protection, though neither tool alone, or both together, brings the risk to zero.

Not necessarily. Many people start treatment based on a tested, visible outbreak rather than a blood test, since routine blood testing without symptoms isn't generally recommended and carries a real false-positive risk. The conversation about which treatment approach fits usually follows an actual diagnosis, however it was reached.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a herpes outbreak needs prompt attention regardless of treatment approach

  • —Sores near or on the eye, or eye pain, redness, and light sensitivity
  • —Severe headache with confusion, neck stiffness, or seizures
  • —Inability to urinate, or pain severe enough to prevent urination
  • —A first outbreak with high fever and widespread sores during pregnancy or with a weakened immune system

Eye involvement, confusion with a severe headache, or an inability to urinate during an outbreak need same-day or emergency evaluation rather than a routine appointment.

This explains the general difference between suppressive and episodic herpes treatment; it is educational information, not medical advice. Choosing between them, and any medication decision, belongs with a clinician familiar with a person's outbreak history.

References

  1. 1.Centers for Disease Control and Prevention (2024). About Genital Herpes. CDC (cdc.gov/herpes). linkSupports that genital herpes has no cure but is manageable with antivirals, including daily suppressive therapy to reduce transmission.
  2. 2.Workowski KA, Bachmann LH, Chan PA, et al. (Centers for Disease Control and Prevention) (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, Vol. 70, No. 4. doi:10.15585/mmwr.rr7004a1 ✓The current comprehensive U.S. evidence-based treatment guidelines, source of record for that both suppressive and episodic antiviral therapy are recognized approaches to managing genital herpes.
  3. 3.Centers for Disease Control and Prevention (2024). Condom Use: An Overview. CDC (cdc.gov/condom-use). linkSupports that consistent, correct condom use is highly effective against STIs spread by genital fluids but provides only partial protection against STIs spread by skin-to-skin contact such as herpes.
  4. 4.US Preventive Services Task Force (2023). Genital Herpes Infection: Serologic Screening. US Preventive Services Task Force (reaffirmation, JAMA 2023). link ✓Supports the 2023 USPSTF recommendation against routine serologic screening for genital herpes in asymptomatic adolescents and adults (Grade D), because of poor test specificity and a high false-positive rate.
  5. 5.Centers for Disease Control and Prevention (2024). Screening for Genital Herpes. CDC (cdc.gov/herpes). linkSupports CDC guidance that routine type-specific serologic HSV screening is not recommended for asymptomatic people, and that testing an active lesion directly is the more appropriate approach when symptoms are present.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library